VIR News and Press, Vir Biotechnology Inc. From 05/03/24

2024-05-03 00:35:24 ET Vir Biotechnology, Inc. (VIR) Q1 2024 Earnings Conference Call May 02, 2024, 04:30 PM ET Company Participants Sasha Damouni Ellis - Executive Vice President, Chief Corporate Affairs Officer Marianne De Backer - Chief Executive Officer Carri...

2024-05-02 16:25:03 ET More on Vir Biotechnology Vir Biotechnology: Making Progress In Hepatitis B And Hepatitis Delta Vir Biotechnology, Inc. (VIR) Q4 2023 Earnings Call Transcript Vir Biotechnology GAAP EPS of -$0.86 beats by $0.15, revenue of $16.79M beats by $10....

– Late-breaker SOLSTICE data abstract accepted for poster presentation at the European Association for the Study of the Liver (EASL) Congress 2024 – – Two additional hepatitis program data readouts on track for the fourth quarter 2024 – – $1.51 b...

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer is scheduled to participate in a fireside chat at the BofA Securities Healthcare Conference 2024 on Tuesday, May 14, at 4:20 p.m. PT / 7:20 p.m. ET. A live webcast of the ...

Vir Biotechnology, Inc. (“Vir” or “the Company”, Nasdaq: VIR) today announced the nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors (the “Board”) at its upcoming annual meeting of stockholders on May 29, 2024 (the ...

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2024, on May 2, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on May 2, 2024. ...

2024-03-26 14:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-15 11:30:03 ET H.C. Wainwright analyst issues UNDERPERFORM recommendation for VIR on March 15, 2024 10:00AM ET. The previous analyst recommendation was Underperform. VIR was trading at $10.54 at issue of the analyst recommendation. The overall analyst consensus :...

2024-03-15 11:30:03 ET J.P. Morgan analyst issues BUY recommendation for VIR on March 15, 2024 10:00AM ET. The previous analyst recommendation was Buy. VIR was trading at $10.54 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current anal...

2024-03-13 11:07:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Since Bill Gates left his position with Microsoft (NASDAQ: MSFT ) he diversified his stock portfolio away from the tech giant. Instead, biotechnology has been is primary interes...